Background: This study aimed to evaluate the role of Dickopff 1 (DKK1) serum levels as a marker for early detection of hepatocellular carcinoma (HCC) and to compare it with alphafetoprotein (AFP) after non-surgical intervention (microwave ablation, radiofrequency ablation) in HCC. Patients and methods: This prospective study was conducted in Al-Mahalla hepatology teaching hospital from June 2015 to June 2017. One hundred and twenty patients were included. They were classified into four groups: Group A: 40 patients with chronic liver disease; Group B: 40 patients with HCC which were divided into 2 main sub groups, group Ba which included HCC patients who were not eligible for ablative therapy and group Bb which included HCC patients who were eligible for ablative therapy; Group C: 20 healthy control subjects matched for age and sex; Group D: 20 HCC patients with negative AFP, DKK1 was done for them. Results: There was a highly significant difference (p < 0.001) between groups regarding serum level of Dickpoff 1 with mean of 1 ng/mL in group A (cirrhotic), 2.38 ng/mL in group B (HCC), and 1.83 ng/mL in group D (AFP negative HCC) in comparison to control group C with mean of 0.54 ng/mL. There was a highly statistically significant difference (p value less =0.01) in the studied groups regarding serum Dickpoff 1 before and after intervention with a mean of 2.38 ng/mL before intervention and mean of 1.37 ng/mL after 1 month of intervention. Conclusion: Serum Dkk-1 has higher sensitivity, specificity, and accuracy in early diagnosis of HCC than AFP.

The highest prevalence of chronic hepatitis C virus (HCV) was reported in Egypt. DAAs has been accessible, with a revealed 12 weeks continued virologic reaction (12w-SVR) above 95% after treatment for 12 weeks duration . was to assess adequacy and wellbeing of Sofosbuvir in addition to Daclatasvir with or without Ribavirin in Egyptian patients persistently contaminated with HCV . Study was done on 200 patients separated similarly to 2 enormous gatherings; bunch I under 65 years and gathering II over 65 years partitioned into 4 subgroups rely upon ribavirin.The first subgroup will take sofosbuvir 400mg and daclatasavir60mg (double treatment gathering), under 65 years of age ( bunch Ia ). The subsequent subgroup will take sofosbuvir 400mg, daclatasvir 60 mg and ribavirin 1000-1200 mg weight based (triple treatment gathering) under 65 years of age ( bunch Ib ). The third subgroup will take sofosbuvir 400 mg, daclatasvir 60 mg(dual treatment group)more than 65 years of age( bunch IIa )and the fourth subgroup will take sofosbuvir 400mg, daclatasvir 60 mg and ribavirin1000-1200 mg weight based(triple treatment gathering) ( bunch IIb ). The current examination show that the treatment was sheltered and compelling in all gatherings with by and large reaction of 96%, 94% 92% and 94% in bunch Ia, Ib, IIa, IIb respectively.

Background: Ulcerative colitis (UC) is the commonest type of inflammatory bowel diseases (IBD) all over the world .Aim of the work: Compare the level of serum anti-outer membrane protein C (anti-Omp C) in UC patients and non-ulcerative colitis patients and correlate its level with the disease activity. Patients and methods:This study included 45 patients with UC and 45 non-ulcerative colitis patients. All cases were submitted to history taking, clinical examination and laboratory analysis (including assessment of antiompc antibodies). The cases in the UC group underwent colonic biopsy followed by microscopic histological examination of the obtained samples. Results: Endoscopic Activity Index for UC shows that 71.2% had active UC while 28.8% had inactive UC. The level of anti-ompc antibodies showed a statistically significant increase in the UC-group as compared with the non-UC group (31.11 ± 21.67 and 16.41 ± 15.06 respectively) (p < 0.001). The active UC group had statistically significantly higher level of anti-ompc antibodies as compared with the inactive cases (38.15 ± 18.02 and 26.61± 15.89 respectively) (p=0.005). ROC curve shows that,the best cut off point of anti-ompc level to identify cases with UC from non-ulcerative group was >13.8 with 63.4% sensitivity and 77.6% specificity (p < 0.001).Conclusion: Anti-OMPC may be a useful marker not only for diagnosis of UC but also in determination of the disease activity among UC patients.

No abstract